Our initial diagnostic yield was 31.7%, which was lower than that of other RASopathy studies (diagnostic yield of 60–70%)7,15, because the patients recruited had already tested negative for PTPN11 and HRAS mutations. This evidence concerns the gene HRAS and RASopathy.